PURPOSE: In this study we have examined the effects of zoledronic acid (ZA), a new-generation bisphosphonate, on prostate cancer (CaP) cells in vitro, and on both osteoblastic and osteolytic CaP metastases in animal models. EXPERIMENTAL DESIGN: In vitro, CaP cells were treated with ZA, and the effects on proliferation, cell cycle, and apoptosis were determined. In vivo, PC-3, and LuCaP 23.1 s.c. and tibial tumors were treated with ZA. Effects on bone and tumor were determined by histomorphometry and immunohistochemistry. RESULTS: ZA decreased proliferation of CaP cells, and caused G(1) arrest and apoptosis of CaP cells in vitro. In vivo, s.c. CaP tumor growth was not affected by ZA. However, growth of osteoblastic and osteolytic metastases of CaP was inhibited significantly in vivo. Matrix metalloproteinase-2, matrix metalloproteinase-9, and Cathepsin K levels were decreased in osteolytic bone metastases after ZA administration. CONCLUSIONS: In conclusion, we have shown that ZA has significant antitumor effects on CaP cells in vitro and in vivo. Antiosteolytic activity and the antitumor effects of this compound could benefit CaP patients with bone metastases.
PURPOSE: In this study we have examined the effects of zoledronic acid (ZA), a new-generation bisphosphonate, on prostate cancer (CaP) cells in vitro, and on both osteoblastic and osteolytic CaP metastases in animal models. EXPERIMENTAL DESIGN: In vitro, CaP cells were treated with ZA, and the effects on proliferation, cell cycle, and apoptosis were determined. In vivo, PC-3, and LuCaP 23.1 s.c. and tibial tumors were treated with ZA. Effects on bone and tumor were determined by histomorphometry and immunohistochemistry. RESULTS:ZA decreased proliferation of CaP cells, and caused G(1) arrest and apoptosis of CaP cells in vitro. In vivo, s.c. CaP tumor growth was not affected by ZA. However, growth of osteoblastic and osteolytic metastases of CaP was inhibited significantly in vivo. Matrix metalloproteinase-2, matrix metalloproteinase-9, and Cathepsin K levels were decreased in osteolytic bone metastases after ZA administration. CONCLUSIONS: In conclusion, we have shown that ZA has significant antitumor effects on CaP cells in vitro and in vivo. Antiosteolytic activity and the antitumor effects of this compound could benefit CaP patients with bone metastases.
Authors: Jinlu Dai; Yi Lu; Chunyan Yu; Jill M Keller; Atsushi Mizokami; Jian Zhang; Evan T Keller Journal: Cancer Res Date: 2010-05-25 Impact factor: 12.701
Authors: Xin Li; Jinhui Liao; Serk In Park; Amy J Koh; William D Sadler; Kenneth J Pienta; Thomas J Rosol; Laurie K McCauley Journal: Bone Date: 2011-03-17 Impact factor: 4.398
Authors: Ilona N Holcomb; Janet M Young; Ilsa M Coleman; Keyan Salari; Douglas I Grove; Li Hsu; Lawrence D True; Martine P Roudier; Colm M Morrissey; Celestia S Higano; Peter S Nelson; Robert L Vessella; Barbara J Trask Journal: Cancer Res Date: 2009-09-22 Impact factor: 12.701
Authors: Agatha Labrinidis; Shelley Hay; Vasilios Liapis; Vladimir Ponomarev; David M Findlay; Andreas Evdokiou Journal: Clin Cancer Res Date: 2009-04-28 Impact factor: 12.531